Literature DB >> 32178373

Reference Values for Skeletal Muscle Mass - Current Concepts and Methodological Considerations.

Carina O Walowski1, Wiebke Braun1, Michael J Maisch2, Björn Jensen2, Sven Peine3, Kristina Norman4,5, Manfred J Müller1, Anja Bosy-Westphal1.   

Abstract

Assessment of a low skeletal muscle mass (SM) is important for diagnosis of ageing and disease-associated sarcopenia and is hindered by heterogeneous methods and terminologies that lead to differences in diagnostic criteria among studies and even among consensus definitions. The aim of this review was to analyze and summarize previously published cut-offs for SM applied in clinical and research settings and to facilitate comparison of results between studies. Multiple published reference values for discrepant parameters of SM were identified from 64 studies and the underlying methodological assumptions and limitations are compared including different concepts for normalization of SM for body size and fat mass (FM). Single computed tomography or magnetic resonance imaging images and appendicular lean soft tissue by dual X-ray absorptiometry (DXA) or bioelectrical impedance analysis (BIA) are taken as a valid substitute of total SM because they show a high correlation with results from whole body imaging in cross-sectional and longitudinal analyses. However, the random error of these methods limits the applicability of these substitutes in the assessment of individual cases and together with the systematic error limits the accurate detection of changes in SM. Adverse effects of obesity on muscle quality and function may lead to an underestimation of sarcopenia in obesity and may justify normalization of SM for FM. In conclusion, results for SM can only be compared with reference values using the same method, BIA- or DXA-device and an appropriate reference population. Limitations of proxies for total SM as well as normalization of SM for FM are important content-related issues that need to be considered in longitudinal studies, populations with obesity or older subjects.

Entities:  

Keywords:  appendicular skeletal muscle mass index; fat-free mass index; sarcopenia; sarcopenic obesity; skeletal muscle area; skeletal muscle mass; skeletal muscle mass index

Mesh:

Year:  2020        PMID: 32178373      PMCID: PMC7146130          DOI: 10.3390/nu12030755

Source DB:  PubMed          Journal:  Nutrients        ISSN: 2072-6643            Impact factor:   5.717


1. Introduction

Beyond the well-established role of ageing associated loss in skeletal muscle mass (SM) (primary sarcopenia) as a risk factor of frailty, morbidity and mortality in older people, a low SM is observed as a result of diseases like malignant cancer, chronic obstructive pulmonary disease, heart failure and renal failure (secondary sarcopenia [1]) and is also an emerging prognostic marker in a number of diseases [2,3,4,5,6,7,8,9,10,11,12]. The etiology for sarcopenia as a risk factor might be partly explained by the correlation between SM and cardiac, respiratory or immune function but remains to be investigated further in order to understand the preventative and therapeutic potential of SM. Muscle not only functions as the major tissue for insulin-stimulated glucose uptake, amino acid storage and thermoregulation, but is also secreting a large number of myokines that regulate metabolism in muscle itself as well as in other tissues and organs including adipose tissue, the liver and the brain [13,14]. The recent popularity of SM outpaced the interest in fat mass (FM) that only has a limited and inconsistent impact on morbidity and mortality [15,16]. The assessment of SM by segmentation of continuous whole body magnetic resonance imaging (MRI) is considered as the gold standard [17]. However, this method is too cumbersome and expensive for clinical practice and is even rarely used in studies with larger sample sizes [17,18]. Instead, single slices at different reference sites measured by MRI or obtained from routine computed tomography (CT) examinations are taken as a proxy for the total tissue volume (e.g., L3 muscle cross-sectional area [17,19]). Most commonly, dual X-ray absorptiometry (DXA) is used to assess appendicular lean soft tissue (ASM, the sum of lean soft tissue from both arms and legs) or fat-free mass (FFM, total lean soft tissue plus bone mineral mass or body weight minus FM) as a proxy for SM. More simple and even non-invasive, the output of bioelectrical impedance analysis (BIA) depends on the reference method used to generate the BIA algorithm and can be FFM [20], ASM, e.g., [21,22,23] or even SM, e.g., [24,25,26,27]. To facilitate comparison between studies and to evaluate individual results for SM in patients, it is important to understand the differences between parameters and cut-offs for SM. These differences are not only method inherent but also depend on characteristics of the study population (e.g., ethnicity, age and disease). Device-specific characteristics by different manufacturers determine the validity and precision of parameters for SM. In addition, the available reference values differ with respect to parametric normalization (linear regression or indexing) to account for body size. Further complexity to the definition of a normal SM is derived from the concept of sarcopenic obesity [28]. Since high levels of FM may adversely affect the quality and function of SM [29,30], a normal SM may also depend on the amount of FM. Different professional associations have published definitions of sarcopenia based on an estimate of SM and impaired muscle strength and/or physical performance [31,32,33,34,35,36,37], but no consensus definition has yet been reached. The aim of this review is not to provide an optimal diagnosis of sarcopenia but to compare current definitions of a low SM considering the impact of the underlying methodological assumptions, limitations and normalization of SM parameters for height, weight, body mass index (BMI) or FM.

2. Methods

In order to identify reference values for SM, seven consensus reports were reviewed [31,32,33,34,35,36,37]. Further studies were identified through reference lists and a search for relevant articles based on the keywords “sarcopenia”, “low muscle mass”, “cut-off sarcopenia”, “reference value sarcopenia”, “sarcopenic obesity”. Only parameters of SM normalized for height, weight, BMI or FM were considered. To be included in this article, studies were required to contain the following information: method of SM assessment (device), cut-off points for SM and description of the reference population including geographical location, sample size, distribution between sexes and age (range and/or standard deviation (SD) ± mean). Only English language articles were considered. Therefore, 64 studies were identified that met the inclusion criteria. Main reasons for the exclusion of articles were duplicate analyses conducted on the same reference population (only the first published paper was included), a missing normalization of reference values, a sample size <200 subjects (sample size <200 subjects will not be representative for both sexes, all ages and BMI-groups), the use of anthropometric measures to determine a low SM and the adoption of previously published cut-offs regarding SM and obesity.

Study Characteristics

Studies that met the inclusion criteria were published between 1998 and 2019 and were performed in 21 countries. The sample size of the individual studies ranged from 200 to 38,099 subjects with an age range between 18 and >90 years. In 36 studies, the authors clearly indicated that the reference population included healthy individuals.

3. Results

Published cut-off points for a low SM normalized by height are presented in Table 1, Table 2 and Table 3 stratified by DXA, BIA and CT. In the majority of studies (14 of 32), SM was measured by DXA using lean soft tissue from the arms and legs normalized by height2 given as appendicular skeletal muscle mass index (ASMI) [22,38,39,40,41,42,43,44,45,46,47,48,49,50]. One study [40] used DXA-derived ASM to predict whole body SM measured by MRI using the equation by Kim et al. [51] that was validated in an ethnically diverse sample of healthy men and women. The range of published cut-off values for ASMI by DXA (without considering different classes of sarcopenia) was 5.86–7.40 kg/m2 in men and 4.42–5.67 kg/m2 in women.
Table 1

Cut-off values and diagnostic criteria of a low muscle mass using dual X-ray absorptiometry (DXA).

ReferenceDevice/SoftwareParameter/Cut-Off by GenderReference Group Characteristics (Mean ± SD)/Diagnostic Criteria (→)
Alkahtani (2017)Lunar iDXA General Electric machine, HealthcareASMIClass I and Class II sarcopeniamen: 7.74 kg/m2 and 6.51 kg/m2n = 232Saudi Arabians
menwomen
n 2320
Age (y)27.1 ± 4.2
BMI (kg/m2)28.1 ± 5.5
→ Class I sarcopenia: 1 SD below the means for young, healthy adults → Class II sarcopenia: 2 SDs below the means for young, healthy adults
Imboden et al. (2017)GE Lunar Prodigy or iDXA(a) ASMImen: 6.35 kg/m2women: 4.92 kg/m2(a) n = 1246US population
menwomen
n 488758
Age (y)20 to 3920 to 39
BMI (kg/m2)NANA
→ 2 SDs below the sex-specific means of young adults
(b) ASMImen: 7.40 kg/m2women: 5.60 kg/m2(b) n = 351US population
menwomen
n 168183
Age (year)70 to 7970 to 79
BMI (kg/m2)NANA
→ sex-specific lowest 20% of study group
Kruger et al. (2015)Hologic Discovery-W,software version 12.7 for Cape TownQDR-4500A, softwareversion 12.5:7 for Soweto(a) ASMIwomen: 4.93 kg/m2(a) n = 238Black South Africans (Cape Town)
menwomen
n 0238
Age (year) 25.8 ± 5.9
BMI (kg/m2) 29.8 ± 8.0
→ 2 SDs below the sex-specific means of young, healthy adults
(b) ASMIwomen: 4.95 kg/m2
(b) n = 371Black South Africans (Soweto)
menwomen
n 0371
Age (year) 35.1 ± 3.2
BMI (kg/m2) 28.8 ± 6.2
→ 2 SDs below the sex-specific means of young, healthy adults
Alemán-Mateo & Ruiz Valenzuela (2014)DPX-MD+, GE LunarASMImen: 5.86 kg/m2women: 4.72 kg/m2SMImen: 6.63 kg/m2women: 5.22 kg/m2SM was predicted using Kim’s equation (Kim et al., 2002)n = 216Mexicans
menwomen
n 13680
Age (year)27.3 ± 5.028.2 ± 5.6
BMI (kg/m2)25.7 ± 3.623.2 ± 3.1
→ 2 SDs below the sex-specific means of young, healthy adults
Gould et al. (2014)DPX-L scanner, software version 1.31; Lunar or Prodigy Pro, LunarASMImen: 6.94 kg/m2women: 5.30 kg/m2n = 682study performed in southeastern Australia
menwomen
n 374308
Age (year)20 to 3920 to 39
BMI (kg/m2)NANA
→ 2 SDs below the sex-specific means of young adults
Marwaha et al. (2014)Prodigy Oracle, GE Lunar Corp.(a) ASMIwomen: 4.42 kg/m2(a) n = 469Indians
menwomen
n 0469
Age (year) 20 to 39
BMI (kg/m2) NA
→ 2 SDs below the sex-specific means of young adults
(b) ASMIwomen: 5.11 kg/m2(b) n = 1045Indians
menwomen
n 01045
Age (year) 44.0 ± 17.1
BMI (kg/m2) 25.0 ± 5.2
→ sex-specific lowest 20% of study group
Yu et al. (2014)Hologic Delphi W4500 densitometer, auto whole body version 12.4ASMImen: 6.52 kg/m2women: 5.44 kg/m2n = 4000Chinese (Hong Kong)
menwomen
n 20002000
Age (year)72.5 ± 5.272.5 ± 5.2
BMI (kg/m2)23.7 ± 3.323.7 ± 3.3
→ lowest quintile
Kim et al. (2012)Hologic Discovery-WASMIClass I and Class II sarcopeniamen: 7.50 kg/m2 and 6.58 kg/m2women: 5.38 kg/m2 and 4.59 kg/m2n = 2513Koreans
menwomen
n 12451268
Age (year)31.0 ± 5.530.8 ± 5.6
BMI (kg/m2)24.0 ± 3.422.1 ± 3.5
→ Class I sarcopenia: 1-2 SDs below the sex-specific means for young, healthy adults → Class II sarcopenia: 2 SDs below the sex-specific means for young, healthy adults
Oliveira et al. (2011)DPX-L, Lunar Radiation CorporationASMIwomen: 5.0 kg/m2n = 349Brazilians
menwomen
n 0349
Age (year) 29.0 ± 7.5
BMI (kg/m2) 23.5 ± 4.5
→ 2 SDs below the sex-specific means of young, healthy adults
Sanada et al. (2010)Hologic QDR-4500A scanner, software version 11.2:3ASMIClass I and Class II sarcopeniamen: 7.77 kg/m2 and 6.87 kg/m2women: 6.12 kg/m2 and 5.46 kg/m2n = 529Japanese
menwomen
n 266263
Age (year)28.2 ± 7.428.0 ± 7.0
BMI (kg/m2)23.0 ± 3.020.8 ± 2.6
→ Class I sarcopenia: 1 SD below the sex-specific means for young, healthy adults → Class II sarcopenia: 2 SDs below the sex-specific means for young, healthy adults
Szulc et al. (2004)Hologic 1000WASMImen: 6.32 kg/m2n = 845study performed in France
menwomen
n 8450
Age (year)64.0 ± 8.0
BMI (kg/m2)28.0 ± 3.7
→ lowest quartile
Newman et al. (2003)QDR 4500A, Hologic, Inc.ASMImen: 7.23 kg/m2women: 5.67 kg/m2Values recommended by the International Working Group on Sarcopenia (Fielding et al., 2011)n = 2984study performed in USA (41% Blacks)
menwomen
n 14351549
Age (year)73.6 ± 2.973.6 ± 2.9
BMI (kg/m2)27.4 ± 4.827.4 ± 4.8
→ sex-specific lowest 20% of study group
Tankó et al. (2002)QDR4500A scanner, Hologic, software version V8.10a:3 and DPX scanner, Lunar Radiation, software versions 3.1 and 3.2(a) ASMIwomen: 6.10 kg/m2(b) ASMIwomen: 5.40 kg/m2n = 216 womenDanes
menwomen
n 0216
Age (year) 30.4 ± 5.3
BMI (kg/m2) NA
→ (a) 1-2 SDs below the sex-specific means for young, healthy, premenopausal women → (b) 2 SDs below the sex-specific means for young, healthy, premenopausal women
Baumgartner et al. (1998)Lunar DPXASMImen: 7.26 kg/m2women: 5.45 kg/m2n = 229US population (non-Hispanic white men and women)
menwomen
n 107122
Age (year)28.7 ± 5.129.7 ± 5.9
BMI (kg/m2)24.6 ± 3.824.1 ± 5.4
→ 2 SDs below the sex-specific means of young, healthy adults

ASMI, appendicular skeletal muscle mass index; BMI, body mass index; DXA, dual X-ray absorptiometry; NA, not available; SD, standard deviation; SM, skeletal muscle mass; SMI, skeletal muscle mass index.

Table 2

Cut-off values and diagnostic criteria of a low muscle mass using bioelectrical impedance analysis (BIA).

ReferenceDevice/SoftwareParameter/Cut-Off by GenderReference Group Characteristics (Mean ± SD)/Diagnostic Criteria (→)
Krzymińska-Siemaszko et al. (2019)InBody 170 analyzer, Biospace Co.ASMImen: 7.35 kg/m2 (20–30 y), 7.38 kg/m2 (18–40 y, 18–39 y, 20–35 y), 7.40 kg/m2 (20–39 y, 20–40 y)women: 5.51 kg/m2 (20–30 y), 5.56 kg/m2 (18–40 y), 5.53 kg/m2 (18–39 y), 5.59 kg/m2 (20–39 y), 5.60 kg/m2 (20–40 y), 5.58 kg/m2 (20–35 y)Authors recommended the highest cut-off points, i.e., 5.60 kg/m2 in women and 7.40 kg/m2 in menn = 1512study performed in Poland (Caucasians)
menwomen
n 635877
Age (year)24.2 ± 5.328.4 ± 6.8
BMI (kg/m2)NANA
total n for men and women depends on age range
→ 2 SDs below the sex-specific means of young, healthy adults
Alkahtani (2017)Tanita MC-980MA, Tanita CorporationInbody 770, Inbody Co.ASMIClass I and Class II sarcopeniamen: 8.68 kg/m2 and 7.45 kg/m2ASMIClass I and Class II sarcopeniamen: 7.29 kg/m2 and 6.42 kg/m2n = 232Saudi Arabians
menwomen
n 2320
Age (year)27.1 ± 4.2
BMI (kg/m2)28.1 ± 5.5
→ Class I sarcopenia: 1 SD below the means for young, healthy adults → Class II sarcopenia: 2 SDs below the means for young, healthy adults
Bahat et al. (2016)Tanita BC 532 model body analysis monitorSMImen: 9.2 kg/m2women: 7.4 kg/m2SM (kg) = 0.566 x FFMn = 301study performed in Turkey
menwomen
n 187114
Age (year)26.8 ± 4.525.9 ± 4.7
BMI (kg/m2)25.5 ± 3.622.4 ± 3.4
→ 2 SDs below the sex-specific means of young, healthy adults
Chang et al. (2013)Tanita BC-418ASMImen: 6.76 kg/m2women: 5.28 kg/m2SMImen: 7.70 kg/m2women: 5.67 kg/m2SM by Janssen et al. (2000) equationn = 998Taiwanese
menwomen
n 498500
Age (year)23.1 ± 3.023.1 ± 2.7
BMI (kg/m2)22.2 ± 3.120.2 ± 2.6
→ 2 SDs below the sex-specific means of young, healthy adults
Yamada et al. (2013)Inbody 720, Biospace Co.ASMImen: 6.75 kg/m2women: 5.07 kg/m2n = 38,099Japanese
menwomen
n 19,79718,302
Age (year)18 to 4018 to 40
BMI (kg/m2)NANA
→ 2 SDs below the sex-specific means of young adults
Masanés et al. (2012)RJL Systems BIA 101SMImen: 8.25 kg/m2women: 6.68 kg/m2SM by Janssen et al. (2000) equationn = 230study performed in Spain
menwomen
n 110120
Age (year)28.6 ± 5.028.2 ± 6.0
BMI (kg/m2)24.6 ± 2.621.9 ± 2.2
→ 2 SDs below the sex-specific means of young, healthy adults
Tanimoto et al. (2012)Tanita MC-190ASMImen: 7.0 kg/m2women: 5.8 kg/m2n = 1719Japanese
menwomen
n 838881
Age (year)26.6 ± 6.728.5 ± 7.3
BMI (kg/m2)22.4 ± 3.220.8 ± 2.9
→ 2 SDs below the sex-specific means of young, healthy adults
Chien et al. (2008)Maltron BioScan 920SMImen: 8.87 kg/m2women: 6.42 kg/m2SM by Janssen et al. (2000) equationn = 200Taiwanese
menwomen
n 100100
Age (year)26.7 ± 5.727.6 ± 5.9
BMI (kg/m2)23.2 ± 3.520.6 ± 2.5
→ 2 SDs or more below the sex-specific means of young, healthy adults
Tichet et al. (2008)Impedimed multifrequency analyserSMImen: 8.60 kg/m2women: 6.20 kg/m2SM by Janssen et al. (2000) equationn = 782French people
menwomen
n 394388
Age (year)30.2 ± 6.129.2 ± 6.3
BMI (kg/m2)23.9 ± 3.022.5 ± 3.4
→ 2 SDs below the sex-specific means of young, healthy adults
Janssen et al. (2004)Valhalla 1990B Bio-Resistance Body Composition AnalyzerSMImoderate and severe sarcopeniamen: 8.51–10.75 kg/m2 and ≤8.50 kg/m2women: 5.76–6.75 kg/m2 and ≤5.75 kg/m2SM by Janssen et al. (2000) equationn = 4499 US population (non-Hispanic White, non-Hispanic Black and Mexican American)
menwomen
n 22232276
Age (year)70.0 ± 7.071.0 ± 8.0
BMI (kg/m2)26.6 ± 4.327.0 ± 5.5
→ receiver operating characteristics

ASMI, appendicular skeletal muscle mass index; BIA, bioelectrical impedance analysis; BMI, body mass index; FFM, fat-free mass; NA, not available; SD, standard deviation; SM, skeletal muscle mass; SMI, skeletal muscle mass index.

Table 3

Cut-off values and diagnostic criteria of a low muscle mass using computed tomography (CT).

ReferenceDevice/SoftwareParameter/Cut-Off by GenderReference Group Characteristics (Mean ± SD)/Diagnostic Criteria (→)
Ufuk & Herek (2019)lumbar CT images(16-detector row, Brilliance)CT L3 SMImen: 44.98 cm2/m2women: 36.05 cm2/m2CT L3 PMImen: 2.63 cm2/m2women: 2.02 cm2/m2n = 270healthy Turkish population
menwomen
n 134136
Age (year)44.3 ± 11.245.0 ± 8.6
BMI (kg/m2)26.4 ± 3.525.4 ± 3.6
→ 2 SDs below the sex-specific means of young adults
Derstine et al. (2018)lumbar CT images(GE Discovery or LightSpeed scanner)(a) CT L3 SMImen: 45.4 cm2/m2women: 34.4 cm2/m2(a) n = 727healthy US population
menwomen
n 317410
Age (year)18 to 4018 to 40
BMI (kg/m2)NANA
→ 2 SDs below the sex-specific means of young adults
(b) CT T10 SMImen: 28.8 cm2/m2women: 20.4 cm2/m2(b) n = 278healthy US population
menwomen
n 122156
Age (year)18 to 4018 to 40
BMI (kg/m2)NANA
→ 2 SDs below the sex-specific means of young adults
(c) CT T11 SMImen: 27.6 cm2/m2women: 19.2 cm2/m2(c) n = 577healthy US population
menwomen
n 241366
Age (year)18 to 4018 to 40
BMI (kg/m2)NANA
→ 2 SDs below the sex-specific means of young adults
(d) CT T12 SMImen: 28.8 cm2/m2women: 20.8 cm2/m2(d) n = 700healthy US population
menwomen
n 299401
Age (year)18 to 4018 to 40
BMI (kg/m2)NANA
→ 2 SDs below the sex-specific means of young adults
(e) CT L1 SMImen: 34.6 cm2/m2women: 25.9 cm2/m2(e) n = 724healthy US population
menwomen
n 315409
Age (year)18 to 4018 to 40
BMI (kg/m2)NANA
→ 2 SDs below the sex-specific means of young adults
(f) CT L2 SMImen: 40.1 cm2/m2women: 30.4 cm2/m2(f) n = 726healthy US population
menwomen
n 315411
Age (year)18 to 4018 to 40
BMI (kg/m2)NANA
→ 2 SDs below the sex-specific means of young adults
(g) CT L4 SMImen: 41.3 cm2/m2women: 34.2 cm2/m2(g) n = 704healthy US population
menwomen
n 305399
Age (year)18 to 4018 to 40
BMI (kg/m2)NANA
→ 2 SDs below the sex-specific means of young adults
(h) CT L5 SMImen: 39.0 cm2/m2women: 30.6 cm2/m2(h) n = 506healthy US population
menwomen
n 211295
Age (year)18 to 4018 to 40
BMI (kg/m2)NANA
→ 2 SDs below the sex-specific means of young adults
van der Werf et al. (2018)lumbar CT images(64-row CT scanner, Sensation 64, Siemens or CT Brilliance 64, Philips)CT L3 SMImen: 44.6 cm2/m2women: 34.0 cm2/m2n = 300healthy Caucasian population
menwomen
n 126174
Age (y)20 to 6020 to 60
BMI (kg/m2)NANA
→ 5th percentile
Benjamin et al. (2017)lumbar CT images(Discovery 750 HD 64-row spectral CT scanner)CT L3 SMImen: 36.54 cm2/m2women: 30.21 cm2/m2n = 275healthy Asian Indians
menwomen
n 139136
Age (year)32.2 ± 9.832.2 ± 9.8
BMI (kg/m2)24.2 ± 3.224.2 ± 3.2
→ 2 SDs below the sex-specific means of young adults
Kim et al. (2017)lumbar CT images(64-slice multidetector CT scanner, Brilliance 64, Philips Healthcare)CT L3 PMImen: 5.92 cm2/m2 (20–39 y), 4.74 cm2/m2 (40–49 y), 4.22 cm2/m2 (50–59 y), 3.74 cm2/m2 (60–69 y), 3.32 cm2/m2 (70–89 y)women: 4.0 cm2/m2 (20–39 y), 2.88 cm2/m2 (40–49 y), 2.43 cm2/m2 (50–59 y), 2.20 cm2/m2 (60–69 y), 1.48 cm2/m2 (70–89 y)n = 1422study performed in Korea
menwomen
n 550872
Age (year)52.4 ± 12.053.3 ± 12.2
BMI (kg/m2)24.5 ± 3.122.8 ± 3.2
total n for men and women depends on age range
→ 2 SDs below the sex-specific means of young, healthy adults
Sakurai et al. (2017)lumbar CT imagesCT L3 SMImen: 43.2 cm2/m2women: 34.6 cm2/m2 n = 569 patients with gastric cancerstudy performed in Japan
menwomen
n 396173
Age (year)66.7 ± 11.266.7 ± 11.2
BMI (kg/m2)22.0 ± 3.422.0 ± 3.4
→ lowest sex-specific quartile
Hamaguchi et al. (2016)lumbar CT images(Aquilion 64, Toshiba Medical Systems)CT L3 PMImen: 6.36 cm2/m2women: 3.92 cm2/m2n = 230healthy Asian population
menwomen
n 116114
Age (year)20 to 4920 to 49
BMI (kg/m2)NANA
→ 2 SDs below the sex-specific means of young adults
Zhuang et al. (2016)lumbar CT imagesCT L3 SMImen: 40.8 cm2/m2women: 34.9 cm2/m2n = 937 patients with gastric cancerstudy performed in China
menwomen
n 730207
Age (year)64.0 ± 15.064.0 ± 15.0
BMI (kg/m2)21.9 ± 3.021.9 ± 3.0
→ optimal stratification
Iritani et al. (2015)lumbar CT imagesCT L3 SMImen: 36.0 cm2/m2women: 29.0 cm2/m2n = 217 patients with hepatocellular carcinomastudy performed in Japan
menwomen
n 14671
Age (year)27 to 9027 to 90
BMI (kg/m2)13.4 to 35.913.4 to 35.9
→ optimal stratification

BMI, body mass index; CT, computed tomography; L, lumbar vertebra; L3, third lumbar vertebra; NA, not available; PMI, psoas muscle index; SD, standard deviation; SMI, skeletal muscle mass index; T, thoracic vertebra.

With ten studies, the second most commonly used method underlying published SM reference values was BIA [21,22,23,24,25,26,52,53,54,55]. To measure SM by BIA, five studies have used the BIA-equation by Janssen et al. [56] to predict SM [24,25,26,53,55]. This BIA-equation was developed and cross-validated against whole body MRI in a sample of 269 Caucasian men and women aged 18 to 86 years with a BMI of 16-48 kg/m2 using a model 101B BIA analyzer (RJL Systems, Detroit, MI, USA) [56]. The authors reported that the BIA-equation is applicable for Caucasian, African-American, and Hispanic populations but has not been validated for the estimation of SM in Asian populations. One study calculated SM by multiplying BIA-derived FFM with a constant factor (0.566) derived from comparison with SM estimates by 24 h creatinine excretion in healthy subjects [52]. The range of cut-offs for ASMI by BIA was 6.75–7.40 kg/m2 in men and 5.07–5.80 kg/m2 in women, whereas cut-offs for skeletal muscle mass index (SMI) by BIA validated against MRI ranged between 7.70 and 9.20 kg/m2 in men and 5.67 and 7.40 kg/m2 in women (without considering severity of sarcopenia). Nine studies used standard diagnostic CT to determine SM cut-off points for single slices [57,58,59,60,61,62,63,64,65]. Skeletal muscle area (SMA) at the level of the third lumbar vertebra (L3 SMA; L3 SMI = L3 SMA/height2, cm2/m2) was used in three studies on patients with cancer [62,64,65]. Cut-off points ranged between 36.00 and 43.20 cm2/m2 in men and 29.00 and 34.90 cm2/m2 in women. Six studies determined sex-specific cut-offs for SM by CT in healthy populations, thereof five in organ donors [57,58,59,60,61,63]. L3 SMI was used in four studies on healthy subjects [57,58,59,60] and three studies with a healthy reference group used CT imaging at the L3 level to measure the psoas muscle mass area (L3 PMA; L3 psoas muscle index (PMI) = L3 PMA/height2, cm2/m2) [57,61,63]. In healthy populations, cut-off values for L3 SMI ranged between 36.54 and 45.40 cm2/m2 in men and 30.21 and 36.05 cm2/m2 in women, whereas thresholds for L3 PMI were 2.63-6.36 cm2/m2 for men and 1.48–4.00 cm2/m2 for women.

Combination of Measures for Muscle mass and Obesity

Table 4 shows reference values of 34 publications for a low SM in combination with different measures of obesity. Cut-offs for a low SM were mostly determined by DXA or BIA, whereas only a few studies reported CT-defined cut-offs in combination with obesity criteria. SM parameters were commonly normalized for height squared or given as % of body weight. In addition, two studies adjusted ASM for BMI [66,67]. Alternative parameters were FM/FFM ratio [68], visceral fat area/thigh muscle area ratio (VFA/TMA) [69] and fat mass index (FMI) in combination with fat-free mass index (FFMI) [70].
Table 4

Cut-off values that combine measures of muscle mass and obesity.

ReferenceDevice/SoftwareParameter/Cut-Off by GenderReference Group Characteristics (Mean ± SD)/Diagnostic Criteria (→)
Prado et al. (2008)CT imagesCT L3 SMI:men: ≤52.4 cm2/m2women: ≤38.5 cm2/m2+BMI ≥ 30 kg/m2n = 250 obese patients with cancers of the respiratory tract and gastrointestinal locationsstudy performed in Canada
menwomen
n 136114
Age (year)64.6 ± 10.263.2 ± 10.5
BMI (kg/m2)33.9 ± 4.434.7 ± 4.3
→ optimal stratification
Martin et al. (2013)CT imagesCT L3 SMI:men: <43 cm2/m2women: <41 cm2/m2for BMI < 25 kg/m2men: <53 cm2/m2for BMI ≥ 25 kg/m2n = 1473 patients with cancers of the respiratory tract and gastrointestinal locationsstudy performed in Canada
menwomen
n 828645
Age (year)64.7 ± 11.264.8 ± 11.5
BMI (kg/m2)26.0 ± 4.925.1 ± 5.8
→ optimal stratification
Muscariello et al. (2016)BIA(RJL 101, Akern SRL)(a) SMI + BMI < 25 kg/m2Class I and Class II sarcopeniawomen: 7.4 and 6.8 kg/m2(a) n = 313study performed in Italy
menwomen
n 0313
Age (year) 28.5 ± 7.6
BMI (kg/m2) 24.1 ± 2.5
→ Class I sarcopenia: 1 SD below the sex-specific means of young adults
→ Class II sarcopenia: 2 SDs below the sex-specific means of young adults
(b) SMI + BMI ≥ 30 kg/m2Class I and Class II sarcopeniawomen: 8.3 and 7.3 kg/m2SM by Janssen et al. (2000) equation(b) n = 361study performed in Italy
menwomen
n 0361
Age (year) 30.9 ± 7.9
BMI (kg/m2) 35.1 ± 4.6
→ Class I sarcopenia: 1 SD below the sex-specific means of young adults
→ Class II sarcopenia: 2 SDs below the sex-specific means of young adults
Nishigori et al. (2016)CT imagesCT L3 SMI (Prado et al. 2008):men: ≤52.4 cm2/m2women: ≤38.5 cm2/m2+visceral fat area (VFA) ≥100 cm2 in both sexesreference group characteristic CT L3 SMI see Prado et al. (2008)
Pecorelli et al. (2016)CT images(a) CT L3 SMI (Prado et al. 2008):men: ≤52.4 cm2/m2women: ≤38.5 cm2/m2+(b) visceral fat area/total abdominal muscle area ratio (VFA/TAMA)men & women: 3.2(a) reference group characteristic CT L3 SMI see Prado et al. (2008)
(b) n = 202 patients with resectable pancreas, periampullarystudy performed in Italy
menwomen
n 10894
Age (year)66.8 ± 10.766.8 ± 10.7
BMI (kg/m2)23.6 ± 3.723.6 ± 3.7
→ optimal stratification
Kwon et al. (2017)DXA(Discovery QDR 4500, Hologic)ASM (as % of body weight)men: 30.98%women: 24.81%+BMI ≥ 25 kg/m2 (based on the definition in the Asian-Pacific region)n = 3550Koreans
menwomen
n 16681882
Age (year)20 to 3920 to 39
BMI (kg/m2)NANA
→ 1 SD below the sex-specific means of young adults
Chiles Shaffer et al. (2017)DXA(Lunar Prodigy Advance with GE EnCore 2006 version 10.51.0006)ASM adjusted for BMImen: <0.725 kg/m2women: <0.591 kg/m2 n = 545study performed in US
menwomen
n 287258
Age (year)79.2 ± 7.277.7 ± 7.3
BMI (kg/m2)27.2 ± 3.827.0 ± 5.2
→ CART analysis
An & Kim (2016)DXA(Discovery-W, Hologic)ASM (as % of body weight)men: 30.1%women: 21.2%+WC ≥ 90 cm in menWC ≥ 80 cm in women(sex-specific cut-off for Asians)n = 5944study performed in Korea
menwomen
n 25023334
Age (year)20 to 3920 to 39
BMI (kg/m2)NANA
→ 1 SD below the sex-specific means of young adults
Cho et al. (2015)(a) DXA(Discovery-W, Hologic)(a) ASM (as % of body weight)men: 30.3%women: 23.8%+WC ≥ 90 cm in menWC ≥ 85 cm in women(a) n = 4987Koreans
menwomen
n 21232864
Age (year)20 to 3920 to 39
BMI (kg/m2)NANA
→ 1 SD below the sex-specific means of young, healthy adults
Oh et al. (2015)DXA(Lunar Corp.)ASM (as % of body weight)men: 44%women: 52%+BMI ≥ 25 kg/m2 n = 1746Koreans
menwomen
n 748998
Age (year)20 to 3920 to 39
BMI (kg/m2)NANA
→ 1 SD below the sex-specific means of young, healthy adults
Lee et al. (2015)DXA(Discovery QDR 4500, Hologic)ASM (as % of body weight)men: 32.2%women: 25.5%+BMI ≥ 25 kg/m2 (based on the criteria of the Asian-Pacific region)n = 2200Koreans
menwomen
n 9601240
Age (year)20 to 3020 to 30
BMI (kg/m2)NANA
→ 1 SD below the sex-specific means of young, healthy adults
Baek et al. (2014)DXA(Lunar Corp.)ASMImen: 6.96 kg/m2women: 4.96 kg/m2ASM (as % of body weight)men: 30.65%women: 23.90%+BMI ≥ 25 kg/m2 (IOTF-proposed classification of BMI for Asia)n = 4192Koreans
menwomen
n 16992493
Age (year)20 to 3920 to 39
BMI (kg/m2)NANA
→ 1 SD below the sex-specific means of young, healthy adults
Cawthon et al. (2014)DXA(QDR 4500, Hologic 2000, Lunar Prodigy)ASM adjusted for BMImen: <0.789women: <0.512recommended by FNIH (Studenski et al., 2014)n = 11,270study performed in US
menwomen
n 75823688
Age (year)65 to 8065 to 80
BMI (kg/m2)NANA
→ CART analysis plus sensitivity analyses
Chung et al. (2013)(a) DXA(fan-beam technology, Lunar Corp.)(a) ASM (as % of body weight)men: 32.5%women: 25.7%+BMI ≥ 25 kg/m2 (IOTF-proposed classification of BMI for Asia)(a) n = 2781study performed in Korea
menwomen
n 11551626
Age (year)20 to 3920 to 39
BMI (kg/m2)NANA
→ 1 SD below the sex-specific means of young, healthy adults
Hwang et al. (2012)DXA(Discovery-W, Hologic)ASM (as % of body weight)men: 29.53%women: 23.20%+WC ≥ 90 cm in menWC ≥ 85 cm in women(Korean abdominal obesity criteria; Lee et al., 2007)n = 2269Koreans
menwomen
n 10031266
Age (year)30.7 ± 5.531.0 ± 5.5
BMI (kg/m2)24.1 ± 3.522.1 ± 3.6
→ 2 SDs below the sex-specific means of young adults
Lee et al. (2012)DXA(Discovery-W, Hologic)ASM (as % of body weight)men: 26.8%women: 21.0%+BMI ≥ 27.5 kg/m2n = 2113Koreans
menwomen
n 9021211
Age (year)20 to 4020 to 40
BMI (kg/m2)NANA
→ 2 SDs below the sex-specific means of young, healthy adults
Kim et al. (2012)DXA(Discovery-W, Hologic)ASM (as % of body weight)Class II sarcopeniamen: 29.1%women: 23.0%ASMIClass II sarcopeniamen: 6.58 kg/m2women: 4.59 kg/m2+WC ≥ 90 cm in men (Lee et al., 2007)WC ≥ 85 cm in womenn = 2513Koreans
menwomen
n 12451268
Age (year)31.0 ± 5.530.8 ± 5.6
BMI (kg/m2)24.0 ± 3.422.1 ± 3.5
→ 2 SDs below the sex-specific means of young, healthy adults
Kim et al. (2011)DXA(Lunar Corp.)ASM (as % of body weight)men: 29.5%women: 23.2%+BMI ≥ 27.5 kg/m2n = 2392study performed in Korea
menwomen
n 10541338
Age (year)20 to 4020 to 40
BMI (kg/m2)NANA
→ 2 SDs below the sex-specific means of young, healthy adults
Kim et al. (2009)DXA(Discovery A, Hologic)(a) ASMImen: 8.81 kg/m2women: 7.36 kg/m2+(b) FMmen: 20.21%women: 31.71%n = 526Koreans
menwomen
n 198328
Age (year)52.2 ± 14.451.2 ± 14.8
BMI (kg/m2)25.2 ± 3.123.9 ± 3.7
→ (a) lower two quintiles
→ (b) two highest quintiles
Rolland et al. (2009)(a) DXA(Lunar DPX, Lunar Corp.)(a) ASMIwomen: 5.45 kg/m2 (Baumgartner et al., 1998)+(a) n = 122US population (non-Hispanic white men and women)
menwomen
n 0122
Age (year) 29.7 ± 5.9
BMI (kg/m2) 24.1 ± 5.4
→ 2 SDs below the sex-specific means of young, healthy adults
(b) DXA(QDR 4500 W, Hologic)(b) FMwomen: 40%(b) n = 1308study performed in France
menwomen
n 01308
Age (year) ≥75
BMI (kg/m2) NA
→ 60th percentile of the healthy study sample
Baumgartner et al. (1998)DXA(Lunar DPX, Lunar Corp.)(a) ASMImen: 7.26 kg/m2women: 5.45 kg/m2+(b) FMmen: 27%women: 38%n = 229US population (non-Hispanic white men and women)
menwomen
n 107122
Age (year)28.7 ± 5.129.7 ± 5.9
BMI (kg/m2)24.6 ± 3.824.1 ± 5.4
(a) → 2SDs below the sex-specific means of young, healthy adults(b) → >sex-specific median
Bahat et al. (2016); Bahat et al. (2018)BIA(Tanita-BC532)(a) SMImen: 9.2 kg/m2women: 7.4 kg/m2SM (kg) = 0.566 × FFM+(a) n = 301study performed in Turkey
menwomen
n 187114
Age (year)26.8 ± 4.525.9 ± 4.7
BMI (kg/m2)25.5 ± 3.622.4 ± 3.4
→ 2 SDs below the sex-specific means of young, healthy adults
(b) FMmen: 27.3%women: 40.7%(b) n = 992study performed in Turkey
menwomen
n 308684
Age (year)75.2 ± 7.275.2 ± 7.2
BMI (kg/m2)27.7 ± 4.330.7 ± 5.6
→ above 60th percentile
Ishii et al. (2016)(a) BIA(Tanita MC-190)(a) ASMImen: 7.0 kg/m2women: 5.8 kg/m2+(a) n = 1719Japanese
menwomen
n 838881
Age (year)26.6 ± 6.728.5 ± 7.3
BMI (kg/m2)22.4 ± 3.220.8 ± 2.9
→ 2 SDs below the sex-specific means of young, healthy adults
(b) BIA(InBody 430, Biospace)(b) FMmen: 29.7%women: 37.2%(b) n = 1731Japanese
menwomen
n 875856
Age (year)≥ 65≥ 65
BMI (kg/m2)NANA
→ highest quintile
Moreira et al. (2016)BIA(InBody R20, Biospace)ASMIwomen: 6.08 kg/m2+WC ≥ 88 cm in women (Brazilian obesity guidelines)n = 491study performed in Northeast Brazil (Whites, Blacks, Pardo)
menwomen
n 0491
Age (year) 50.0 ± 5.6
BMI (kg/m2) 29.0 ± 4.8
→ 20th percentile
Kemmler et al. (2016)BIA(InBody 770, Biospace)(a) ASMIwomen: 5.66 kg/m2(a) n = 689study performed in Germany (Caucasians)
menwomen
n 0689
Age (year) 18 to 35
BMI (kg/m2) NA
→ 2 SDs below the sex-specific means of young, healthy adults
(b) ASMIwomen: 5.99 kg/m2+BMI ≥ 30 kg/m2 (NIH)FM ≥ 35% (WHO)(b) n = 1325study performed in Germany (Caucasians)
menwomen
n 01325
Age (year) 76.4 ± 4.9
BMI (kg/m2) 26.7 ± 4.3
→ lowest quintile
Lee et al. (2016)BIA(InBody 720, Biospace)(a) SMI (as % of body weight)men: 38.2 %women: 32.2%SM by Janssen et al. (2000) equation+(a) n = 273study performed in Korea
menwomen
n 157116
Age (year)25.5 ± 2.926.1 ± 4.6
BMI (kg/m2)24.1 ± 3.020.7 ± 2.6
→ 2 SDs below the sex-specific means of young, healthy adults
(b) FMmen: 25.8%women: 36.5%(b) n = 309study performed in Korea
menwomen
n 85224
Age (year)70.7 ± 6.366.4 ± 7.2
BMI (kg/m2)NANA
→ two highest quintiles
Biolo et al. (2015)BIA(Human IM-Plus, DS, Dieto System, BIA 101, Akern Srl, Tanita BC418MA, Tanita Corp.)FM/FFM ratio > 0.8n = 200study performed in Italy and Slovenia
menwomen
n 89111
Age (year)48.0 ± 12.051.0 ± 12.0
BMI (kg/m2)35.6 ± 6.235.5 ± 5.4
De Rosa et al. (2015)BIA(Human IM Plus II–DS Medical)SMImoderate and severe sarcopeniamen: 8.44–9.53 kg/m2 and ≤8.43 kg/m2women: 6.49–7.32 kg/m2 and ≤6.48 kg/m2SMI (as % of body weight)moderate and severe sarcopeniamen: 28.8–35.6% and ≤28.7%women: 23.1–28.4% and ≤23.0%SM by Janssen et al. (2000) equation+BMI ≥ 30 kg/m2n = 500Italians
menwomen
n 100400
Age (year)27.0 ± 7.025.0 ± 6.0
BMI (kg/m2)25.8 ± 5.725.2 ± 5.7
→ moderate sarcopenia: within 1 to 2 SDs below the sex-specific means of young, healthy adults → severe sarcopenia: 2 SDs below the sex-specific means of young, healthy adults
Atkins et al. (2014)BIA(Bodystat 500, Bodystat Ltd.)FFMImen: ≤16.7 kg/m2FFM (equation by Deurenberg et al., 1991)+FMI > 11.1 kg/m2n = 4045study performed in UK (> 99 % white Europeans)
menwomen
n 40450
Age (year)60 to 79
BMI (kg/m2)NA
→ lowest two-fifths of FFMI
Baek et al. (2013)BIA(InBody 520, Biospace)ASMImen: 10.70 kg/m2women: 8.60 kg/m2+BMI > 25 kg/m2 (WHO definition)n = 1150study performed in Korea
menwomen
n 618532
Age (year)43.6 ± 11.543.6 ± 11.5
BMI (kg/m2)24.6 ± 3.324.6 ± 3.3
→ 50th percentile of healthy study sample
Gomez-Cabello et al. (2011)BIA(Tanita BC 418-MA)(a) SMImen: 8.61 kg/m2women: 6.19 kg/m2(b) FMmen: 30.33%women: 40.9%SM by Janssen et al. (2000) equationn = 3136Spaniards
menwomen
n 6782198
Age (year)72.4 ± 5.572.1 ± 5.2
BMI (kg/m2)NANA
→ (a) two lower quintiles → (b) two highest quintiles
Lou et al. (2017)CT imagesCT L3 SMI (Zhuang et al., 2016)men: ≤40.8 cm2/m2women: ≤34.9 cm2/m2+BMI ≥ 23 kg/m2 (WHO definition for Asians)Predefined cut-off values for sarcopenia and obesity
Ramachandran et al. (2012)CT images(Somatom Sensation 10 CT scanner)adjusted thigh muscle area:men: 110.7 cm2women: 93.8 cm2+(1) BMI ≥ 27 kg/m2(2) WC ≥ 102 cm for menWC ≥ 88 cm for womenn = 539study performed in US
menwomen
n 280259
Age (year)71.1 ± 0.471.1 ± 0.4
BMI (kg/m2)NANA
→ lowest sex-specific tertile
Lim et al. (2010)CT images(Brilliance 64, Philips)Visceral fat area (VFA)/thigh muscle area (TMA)men: 0.93women: 0.90n = 264Koreans
menwomen
n 126138
Age (year)20 to 8820 to 88
BMI (kg/m2)NANA
→ VFA/TMA median higher 50th percentile of the healthy study sample

ASM, appendicular skeletal muscle mass; ASMI, appendicular skeletal muscle mass index; BMI, body mass index; BIA, bioelectrical impedance analysis; CART, classification and regression tree analysis; CT, computed tomography; DXA, dual X-ray absorptiometry; FFM, fat-free mass; FFMI, fat-free mass index; FM, fat mass; FMI, fat mass index; FNIH, Foundation for the National Institutes of Health; IOTF, International Obesity Taskforce; L3, third lumbar vertebra; NA, not available; NIH, National Institutes of Health; SD, standard deviation; SM, skeletal muscle mass; SMI, skeletal muscle mass index; TAMA, total abdominal muscle area; TMA, thigh muscle area; VFA, visceral fat area; WC, waist circumference; WHO, World Health Organization.

Prado et al. [71] published CT-derived SMI cut-offs determined in a population of obese (BMI ≥ 30 kg/m2) Canadians with tumors of the respiratory or gastrointestinal tract. In 2013, this CT database was extended by Martin et al. [72] and low SM reference values were reported for subjects with normal weight and overweight according to BMI classifications. In both studies, optimal stratification was used to determine the threshold of mortality. Many studies adopted the criteria proposed by Prado et al. [71] and Martin et al. [72] (e.g., [73,74,75]). Only one further study developed BMI-dependent reference values for SM [76]. Although some studies referenced the cut-offs by Prado et al. [71], reported thresholds differ from the original work (e.g., [77,78]). These reported values were then cited in further studies [79]. In most studies, obesity was defined as BMI ≥ 30 kg/m2 [71,76,80,81]. Alternative BMI thresholds were 27.5 kg/m2 [82,83], 27 kg/m2 [84], 25 kg/m2 [72,85,86,87,88,89,90] or 23 kg/m2 [91]. Furthermore, sex and ethnic-specific waist circumference (WC) thresholds for central obesity were considered [44,84,92,93,94,95]. Other criteria include %FM [50,81,96,97,98,99,100,101], visceral fat area [73] or fat-muscle ratios like visceral fat area (VFA) to total abdominal muscle area (TAMA) [74]. Table 5 displays cut-offs and average values for body composition stratified into groups of subjects with underweight, normal weight, overweight and obesity. Cut-offs for FMIDXA were released by the National Health and Nutrition Examination Survey (NHANES; [102]) and respective BMI-dependent normal values for FFMIDXA were calculated as BMI minus FMI. For each given BMI displayed in Table 5, corresponding normal value for SMIMRI were calculated using a stepwise regression analysis (SMIMRI, men = 0.479 × FFMIDXA −0.017 × age + 0.683 and SMIMRI, women = 0.348 × FFMIDXA − 0.011 × age + 1.971) in a healthy Caucasian population. In addition, respective values for SMIBIA validated against MRI were generated based on a young and healthy Caucasian population using linear regression analysis (SMIBIA, men = 0.168 × BMI + 5.49 (R2 = 0.53, standard error of estimate (SEE) = 0.514) and SMIBIA, women = 0.159 × BMI + 3.72 (R2 = 0.61, SEE = 0.465)). Adjacent to the average SMIBIA (median) for each BMI, cut-offs with two SDs below the sex-specific mean of the young and healthy population were shown.
Table 5

Generation of cut-offs for SMI (corresponding to BMI thresholds) based on FFMI.

BMI(kg/m2)FMIDXA (kg/m2)(Kelly et al., 2009)FFMIDXA (kg/m2)(Modified according to Kelly et al., 2009)SMIMRI (kg/m2)(1.5 T Siemens Avanto MRI Scanner)SMIBIA_median (kg/m2)(mBCA 515, Seca)SMIBIA_-2SDs (kg/m2)(mBCA 515, Seca)
Caucasian men<18.5<2.915.6 8.6>7.6
>25>6.019.09.859.7>8.7
>30>8.921.110.7110.5>9.5
>35>11.923.112.1511.4>10.3
>40>15.025.013.6712.2>11.2
Caucasian women<18.5<4.913.66.656.7>5.7
>25>9.215.87.497.7>6.8
>30>12.917.18.158.5>7.6
>35>16.818.28.999.3>8.4
>40>20.619.49.7410.1>9.2

BMI, body mass index; FMIDXA, fat mass index by dual X-ray absorptiometry (QDR 4500A fan beam densitometer (Hologic, Inc., Bedford, MA, Hologic Discovery software version 12.1)); FFMIDXA, fat-free mass index by dual X-ray absorptiometry; SMIMRI, skeletal muscle mass index by magnetic resonance imaging calculated by stepwise regression analysis (n = 410, 219 women (age: 38 ± 13 years, BMI: 27.7 ± 6.5 kg/m2) and 191 men (age: 41 ± 14 years, BMI: 27.7 ± 5.0 kg/m2) (detailed description of the segmentation procedure given elsewhere (Schautz et al., 2012)); SMIBIA_median, skeletal muscle mass index by bioelectrical impedance analysis given as median calculated by linear regression analysis (n = 529, 264 women (27 ± 6 years, BMI: 23.9 ± 3.6 kg/m2) and 265 men (28 ± 6 years, BMI: 25.2 ± 3.2 kg/m2) (detailed description of the BIA measurement procedure given elsewhere (Bosy-Westphal et al., 2017)); SMIBIA_-2SDs, skeletal muscle mass index by bioelectrical impedance analysis given as 2 SDs below the sex-specific mean calculated as linear regression analysis.

4. Discussion

SM has evolved as the most promising body composition parameter associated with health risk in ageing and many chronic diseases [1]. Evaluation of SM is complicated by a variety of available methods that provide different outcome parameters as a proxy for total body SM. Therefore, it is important to have accurate reference values that apply to the patient or population under study as well as to the respective body composition method. In this review, we identified multiple published reference values for discrepant parameters of SM (Table 1, Table 2, Table 3 and Table 4), discussed the differences in the underlying assumptions and limitations as well as different concepts for normalization of SM parameters for height, weight, BMI or FM. Imaging technologies are thought to provide the best assessment of SM. Briefly, segmentation of transversal images by special software (e.g., SliceOmatic Tomovision, version 4.3; Montreal, Québec, Canada) results in muscle areas that are multiplied by the correspondent slice thickness to calculate muscle volume [27] that is transformed to SM by assuming a constant density (1.04 kg/L) of adipose tissue-free SM [103]. Muscles at the head, hands and feet are commonly neglected in this approach. The precision of whole body SMMRI is high (intra-observer coefficient of variation = 1.8% [104]). Reference data for total SM based on the gold standard whole body MRI (Table 5) are scarce due to high costs and cumbersome image-segmentation [17,18]. However, whole body MRI was integrated in the assessment of current large and representative national databases like the UK biobank [105] or the national cohort (NAKO) in Germany [106]. Future evaluation of these databases will provide the basis of statistically derived normal values whereas prospective investigation of mortality or correlation with frailty, fracture risk, glucose or amino acid metabolism would allow to establish even more meaningful disease-specific cut-offs. Instead of whole body imaging, reference values for L3 single slices are frequently published (Table 3 and Table 4), especially in patients where CT images are routinely applied for cancer staging. The use of these cut-offs may be specific for the population studied and transferability of the results to other patient groups needs to be investigated. Radiation exposure is a major limitation that confines the application of CT to individual transversal images or the secondary analysis of routine clinical measurements. As a further drawback, clinical CT protocols for L3 are not standardized across hospital sites. SMA at L1, L2, L4, L5, and the thoracic vertebra T12, T11, and T10 were reported to be suitable alternatives to SMA measured at L3 [58]. Nonetheless, there are also advantages of CT images with a high resolution and precision of the measurement. Most studies report the precision of single slice CT scan analysis to range between 1% and 2% [107]. Thus, automated segmentation is facilitated by using a characteristic range of Hounsfield units for fat-free muscle tissue [107,108]. CT can also differentiate individual muscle or muscle groups and can thus for example investigate the impact of pectoralis muscle area for survival at the Intensive Care Unit [12] because respiratory musculature may determine weaning from mechanical ventilation. On the other hand, characteristic changes in the Hounsfield distribution of muscle can reveal qualitative changes of the tissue (e.g., fatty infiltration or edema) that have been found to be of prognostic value [71]. DXA is the most commonly used method for assessment of SM (Table 1). Lean soft tissue at the arms and legs (ASM) is highly correlated with muscle volume derived from imaging studies (correlation coefficients ranging from 0.77 to 0.97 for both, whole body and regional scans [51,109,110,111,112,113,114,115]). However, only 44% of total lean soft tissue is derived from extremities (unpublished results) and only part of total lean soft tissue is SM. Therefore, SM measured by DXA is considerably higher when compared with muscle volume measured by imaging technologies [27,116]. Precision errors for total ASM are reported to be low (1–3%), device specific and depend on population characteristics like age or prevalence of obesity [117]. BIA can assess SM, ASM or FFM, depending on the reference method used to generate the BIA-algorithm. The choice of the BIA-algorithm not only depends on the desired target-parameter but also on the agreement between the BIA-device or reference population used to generate the BIA-algorithm and the BIA-device and patient characteristics to be evaluated [118]. However, in two studies, the equation by Janssen et al. [56] that is not suitable for Asians was used to predict SM in Asian populations [53,55] with only one study providing a validation in 41 Taiwanese people (age: 20–99 years; BMI: 17.6–34.6 kg/m2) [55]. Except for the study by Masanés et al. [26], all other studies used different BIA devices than Janssen et al. [56] (Table 2). Validity and precision of BIA results differ between manufacturers and depend on the hardware as well as the appropriate validation of the BIA-algorithm [119]. Discrepancies in the assumptions of the homogeneous bioelectrical model that lead to a higher measurement error occur with changes in hydration (e.g., edema) and with differences in body shape that are associated with aging (decreasing limb relative to trunk diameter), obesity (apple and pear shape of body fat distribution) and ethnicity (trunk to leg length, regional adiposity and muscularity). Therefore, segmental BIA that can measure the relative contribution of trunk and extremities to total body conductivity may help to reduce assumptions on body shape leading to an improved prediction compared with conventional wrist-ankle measurements [27]. The accuracy of phase-sensitive segmental BIA compared with MRI as a reference is clinically acceptable when whole body SM was assessed (two SDs: 11–12% for different ethnicities) but it was low when small compartments of the body were assessed (e.g., two SDs: 20–29% for the arms) [27].

4.1. Limitations of Proxies for Total Skeletal Muscle

Single SMA at L3 level turned out to be the best compromise site to assess volumes of total SM together with visceral adipose tissue (VAT) and subcutaneous adipose tissue (SAT) (r = 0.832–0.986; p < 0.01 [17]). Furthermore, SMA at L3 is considered as a valid proxy for whole body FFM (r = 0.940; p < 0.001 [120]). Other authors reported high correlations between single abdominal SMA at L4-L5 intervertebral space and total SM (r = 0.710–0.920 [121]), whereas the use of PMI to determine whole body SM is controversial because psoas is a relatively small muscle. A good correlation between PMI and SMI measured by BIA in healthy 35 Asian liver donors (r = 0.737; p < 0.001) and a moderate correlation in 137 living donor liver transplantation recipients (r = 0.682; p < 0.001) were found [63]. Other authors argue that L3 PMA is not representative of total SM [122,123]. Despite acceptable correlations, the accuracy of single images is limited in individual cases. Likewise, it is well established that the correlation between BMI and FM is fairly good at the population level whereas at the individual level BMI is only a poor indicator of adiposity [124]. In addition, validity of the assessment of changes in SM during follow-up is limited by the use of individual images from L3 or mid-thigh. These images cannot be used as pars pro toto because of regional differences in changes of muscle volume with age or obesity (e.g., the contribution of SMMRI at the arms and legs to ASM tended to decrease at higher adiposity in both genders [104]). Similarly, ASM has limitations to assess the change in total SM with ageing or overweight and obesity. Since lean soft tissue from the extremities also contains lean compartments from connective tissue (e.g., skin and adipose tissue), SM accounts for only about 50% of FFM in obesity [116]. ASM was therefore shown to overestimate appendicular SM assessed by MRI with increasing BMI [27]. In line with this finding, DXA was also shown to underestimate the age-related loss of thigh muscle mass in comparison with MRI [125]. Furthermore, DXA measures of change in lean mass before and 10-week after resistance training were only modestly associated with MRI measures of change in muscle volume [126]. In summary, the random error of single images or ASM as a proxy for total SM limits the applicability of these substitutes in individual cases and together with the systematic error limit the accurate detection of changes in SM.

4.2. Normalization of Skeletal Muscle Mass for Body Size and Obesity

Normalization of lean mass for weight is inappropriate because two people with the same %FFM who differ in height have a different nutritional status, with the taller person having a lower muscularity [127]. FFM has been shown to scale to height with a power of around two in different ethnicities, ranging from 1.86 in non-Hispanic white women to 2.32 in non-Hispanic black men [128]. Consequently, appropriate normalization of total SM, SM-area, ASM and FFM is performed for height2. In addition to the physiologic increase in SM with height, there is also an increase in SM with weight gain that depends on the initial amount of FM [129]. The evaluation of SM may thus also depend on the amount of FM. With increasing obesity, adverse effects on myocyte metabolism, muscle tissue composition and peak force generation can be mediated via paracrine signaling of proinflammatory immune cells in intermuscular adipose tissue [30]. The same SM at a higher FM may also lead to a limitation of strength and increased disability because at the same work load, energy expenditure and muscle force are higher for a person with obesity [130]. In line with these mechanisms, patients with a low SM and a concomitant high FM were shown to have a higher morbidity and mortality when compared to patients with a high FM only (for review see [131]). However, it remains unclear whether the risk of a low SM and a high FM is additive or if the risk of a high FM is disproportionally higher at a concomitantly low SM. Published definitions of sarcopenic obesity use BMI to assess overweight and obesity in combination with fixed cut-offs for a low SM that are derived from subjects with normal weight and/or overweight [72,76]. To the best of our knowledge, all current definitions disregard the relationship between fat and lean mass that can be investigated by applying the Forbes rule (energy partitioning, i.e., the fraction of energy lost or gained as protein, is a nonlinear function of FM [129]) or the Hattori chart (two dimensional plot of FMI vs. FFMI [132]). Table 5 provides novel BMI-dependent SMI cut-offs. The combination of FFMI with FMI [133], %FM [6,8] or BMI [134] facilitate to investigate the proportional contribution of fat and lean compartments to health risk as well as their presumable interaction. An attractive alternative to the simultaneous use of two indices is integration of information on fat and lean compartments in one index as FM/FFM2. This index was proposed by Wells and Victoria who determined the appropriate power by which to raise the denominator from regressing FM on FFM [135]. The usefulness of this index needs to be investigated in future studies because it depends on a linear correlation between FM and FFM2, as well as on absence of heteroscedasticity. Beyond diverse methods of normalization (e.g., appendicular lean mass (ALM) adjusted by BMI [66,67], FFM normalized for body surface area (FFMBSA = (weight [kg]0.425 × height [m]0.725) × 0.007184 [20])) heterogeneous outcome parameters (ASMI, SMI, L3 SMI, L3 PMI, FFMI) and a discrepant nomenclature for the same outcome parameter as well as different ways of reporting reference values hinder the comparison between studies. ASMI (i.e., appendicular skeletal muscle mass/height2) and SMI (total skeletal muscle mass/height2) were the most commonly used denominations within publications and therefore consistently applied in Table 1, Table 2, Table 3, Table 4 and Table 5. A great variety of different notations for the same outcome parameter were found for (a) SMI: e.g., skeletal muscle mass index, SMMI [52], muscle mass index, MMI [25,26], total skeletal muscle index, TSMI [53], total body skeletal muscle mass index, TBSMI [40] and also (b) ASMI: e.g., appendicular skeletal muscle mass index, ASMMI [136], appendicular muscle mass index, AMI (appendicular muscle mass (AMM)/height2) [54], relative appendicular skeletal muscle index, RASM [47,137], relative skeletal muscle mass index [138] and appendicular lean mass index (ALM/height2) [21]. In contrast to the heterogeneous nomenclature, some studies apply the same term “SMI” for different outcome parameters: e.g., ALM/BMI [66,67], ASM/height2 [46,139,140], ALM/height2 [141], ASM/body weight [53] and SM/body weight × 100 [25,137,142,143,144]. In cancer studies, SMI is normally defined as SMA/height2 [62,71,72]. Thus, a consistent nomenclature for proxies of SM is needed in order to facilitate comparison between studies. Moreover, suitable reference values require an appropriate sample size ideally comprised of healthy or “normal” subjects (normative approach) or derive cut-offs from an older population or a group of patients (stratification approach). In addition, reference values can be reported using parametric methods, like Z-scores or 2 SDs below the mean, that rely on normal distribution of the data, on the absence of residual associations, and on constant variance of the normalized measurements throughout the entire sample (absence of heteroscedasticity, logarithmic transformation of the dependent variables or weighted regression models). In Table 1, Table 2, Table 3 and Table 4, most studies used cut-off thresholds for low SM on the basis of young healthy adults’ reference groups according to the recommendations proposed by the European Working Group on Sarcopenia in Older People [32]. The majority of these studies used two SDs below the means of healthy young subjects as a cut-off, e.g., [21,39,40,44,45,50] whereas other studies defined a low SM as one SD below the mean, e.g., [85,90,94,95]. Six articles stratified the cut-offs according to severity of a low SM [22,44,46,49,76,80]. One SM threshold was based on the fifth percentile [59] or on the 20th percentile [92] or on the 50th percentile [89]. Other studies used the sex-specific lowest quintiles [43], quartiles [47,62], tertiles [84], the lower two quintiles of the study population [98,100] or the lowest 20% of the distribution [38,42,48]. In one study, receiver operating characteristics analysis was used to develop SM cut-offs associated with physical disability [24]. In four studies, optimal stratification was used to determine the SM threshold of mortality risk in cancer patients [64,65,71,72]. Further diagnostic criteria applied classification and regression tree analysis [66,67].

5. Conclusions and Recommendations

In summary, published reference values for SM differ widely dependent on the outcome parameter and reference population. Results should consider the limitation of all proxies for total SM with respect to application in individual cases as well as for measurement of changes in SM. To facilitate comparison between results of different studies, authors should use a unified nomenclature for outcome parameters and indicate the device and software version of the body composition analyzer. In addition, the choice of body composition method should depend on the aim of the study. For assessment of changes in SM and evaluation of individual patients, a high precision is required that is, for instance, not fulfilled when segmental bioelectrical impedance is used to assess limb SM. The adverse effects of obesity on muscle quality and function may lead to an underestimation of sarcopenia in obesity and therefore requires normalization of SM for FM.
  140 in total

1.  Appendicular lean tissue mass and the prevalence of sarcopenia among healthy women.

Authors:  László B Tankó; Lusine Movsesyan; Ulrik Mouritzen; Claus Christiansen; Ole L Svendsen
Journal:  Metabolism       Date:  2002-01       Impact factor: 8.694

2.  Prevalence of sarcopenia and sarcopenic obesity in the Korean population based on the Fourth Korean National Health and Nutritional Examination Surveys.

Authors:  Young-Sang Kim; Yunhwan Lee; Yoon-Sok Chung; Duck-Joo Lee; Nam-Seok Joo; Doohee Hong; Go eun Song; Hyeon-Jeong Kim; Yong Jun Choi; Kwang-Min Kim
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2012-03-19       Impact factor: 6.053

3.  A cross-sectional study of sarcopenia in Japanese men and women: reference values and association with cardiovascular risk factors.

Authors:  K Sanada; M Miyachi; M Tanimoto; K Yamamoto; H Murakami; S Okumura; Y Gando; K Suzuki; I Tabata; M Higuchi
Journal:  Eur J Appl Physiol       Date:  2010-09       Impact factor: 3.078

4.  Low relative skeletal muscle mass (sarcopenia) in older persons is associated with functional impairment and physical disability.

Authors:  Ian Janssen; Steven B Heymsfield; Robert Ross
Journal:  J Am Geriatr Soc       Date:  2002-05       Impact factor: 5.562

5.  Prevalence of sarcopenia in healthy community-dwelling elderly in an urban area of Barcelona (Spain).

Authors:  F Masanes; A Culla; M Navarro-Gonzalez; M Navarro-Lopez; E Sacanella; B Torres; A Lopez-Soto
Journal:  J Nutr Health Aging       Date:  2012-02       Impact factor: 4.075

6.  Predictors of 6-minute walk test results in lean, obese and morbidly obese women.

Authors:  M Hulens; G Vansant; A L Claessens; R Lysens; E Muls
Journal:  Scand J Med Sci Sports       Date:  2003-04       Impact factor: 4.221

7.  Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study.

Authors:  Carla M M Prado; Jessica R Lieffers; Linda J McCargar; Tony Reiman; Michael B Sawyer; Lisa Martin; Vickie E Baracos
Journal:  Lancet Oncol       Date:  2008-06-06       Impact factor: 41.316

8.  Sarcopenia: revised European consensus on definition and diagnosis.

Authors:  Alfonso J Cruz-Jentoft; Gülistan Bahat; Jürgen Bauer; Yves Boirie; Olivier Bruyère; Tommy Cederholm; Cyrus Cooper; Francesco Landi; Yves Rolland; Avan Aihie Sayer; Stéphane M Schneider; Cornel C Sieber; Eva Topinkova; Maurits Vandewoude; Marjolein Visser; Mauro Zamboni
Journal:  Age Ageing       Date:  2019-01-01       Impact factor: 10.668

9.  Sarcopenic obesity and risk of cardiovascular disease and mortality: a population-based cohort study of older men.

Authors:  Janice L Atkins; Peter H Whincup; Richard W Morris; Lucy T Lennon; Olia Papacosta; S Goya Wannamethee
Journal:  J Am Geriatr Soc       Date:  2014-01-15       Impact factor: 5.562

10.  Pitfalls in the measurement of muscle mass: a need for a reference standard.

Authors:  Fanny Buckinx; Francesco Landi; Matteo Cesari; Roger A Fielding; Marjolein Visser; Klaus Engelke; Stefania Maggi; Elaine Dennison; Nasser M Al-Daghri; Sophie Allepaerts; Jurgen Bauer; Ivan Bautmans; Maria Luisa Brandi; Olivier Bruyère; Tommy Cederholm; Francesca Cerreta; Antonio Cherubini; Cyrus Cooper; Alphonso Cruz-Jentoft; Eugene McCloskey; Bess Dawson-Hughes; Jean-Marc Kaufman; Andrea Laslop; Jean Petermans; Jean-Yves Reginster; René Rizzoli; Sian Robinson; Yves Rolland; Ricardo Rueda; Bruno Vellas; John A Kanis
Journal:  J Cachexia Sarcopenia Muscle       Date:  2018-01-19       Impact factor: 12.910

View more
  21 in total

1.  Once-Weekly Semaglutide Induces an Early Improvement in Body Composition in Patients with Type 2 Diabetes: A 26-Week Prospective Real-Life Study.

Authors:  Sara Volpe; Giuseppe Lisco; Davide Racaniello; Margherita Fanelli; Valentina Colaianni; Alfredo Vozza; Vincenzo Triggiani; Carlo Sabbà; Cosimo Tortorella; Giovanni De Pergola; Giuseppina Piazzolla
Journal:  Nutrients       Date:  2022-06-10       Impact factor: 6.706

2.  Bio-Electrical Impedance Analysis: A Valid Assessment Tool for Diagnosis of Low Appendicular Lean Mass in Older Adults?

Authors:  Jantine van den Helder; Amely M Verreijen; Carliene van Dronkelaar; Robert G Memelink; Mariëlle F Engberink; Raoul H H Engelbert; Peter J M Weijs; Michael Tieland
Journal:  Front Nutr       Date:  2022-06-02

3.  Definition and Diagnostic Criteria for Sarcopenic Obesity: ESPEN and EASO Consensus Statement.

Authors:  Lorenzo M Donini; Luca Busetto; Stephan C Bischoff; Tommy Cederholm; Maria D Ballesteros-Pomar; John A Batsis; Juergen M Bauer; Yves Boirie; Alfonso J Cruz-Jentoft; Dror Dicker; Stefano Frara; Gema Frühbeck; Laurence Genton; Yftach Gepner; Andrea Giustina; Maria Cristina Gonzalez; Ho-Seong Han; Steven B Heymsfield; Takashi Higashiguchi; Alessandro Laviano; Andrea Lenzi; Ibolya Nyulasi; Edda Parrinello; Eleonora Poggiogalle; Carla M Prado; Javier Salvador; Yves Rolland; Ferruccio Santini; Mireille J Serlie; Hanping Shi; Cornel C Sieber; Mario Siervo; Roberto Vettor; Dennis T Villareal; Dorothee Volkert; Jianchun Yu; Mauro Zamboni; Rocco Barazzoni
Journal:  Obes Facts       Date:  2022-02-23       Impact factor: 4.807

4.  Longitudinal changes in muscle power compared to muscle strength and mass.

Authors:  Sabine Wiegmann; Dieter Felsenberg; Gabriele Armbrecht; Roswitha Dietzel
Journal:  J Musculoskelet Neuronal Interact       Date:  2021-03-01       Impact factor: 2.041

5.  Z-score of the log-transformed A Body Shape Index predicts low muscle mass in population with abdominal obesity: The U.S. and Korea National Health and Nutrition Examination Survey.

Authors:  Shinje Moon; Yoon Jung Kim; Jae Myung Yu; Jun Goo Kang; Hye Soo Chung
Journal:  PLoS One       Date:  2020-11-24       Impact factor: 3.240

6.  Polish version of SARC-F to assess sarcopenia in older adults: An examination of reliability and validity.

Authors:  Roma Krzymińska-Siemaszko; Ewa Deskur-Śmielecka; Aleksandra Kaluźniak-Szymanowska; Arkadiusz Styszyński; Katarzyna Wieczorowska-Tobis
Journal:  PLoS One       Date:  2020-12-21       Impact factor: 3.240

7.  Association between the recognition of muscle mass and exercise habits or eating behaviors in female college students.

Authors:  Tomoki Mase; Kumiko Ohara; Katsumasa Momoi; Harunobu Nakamura
Journal:  Sci Rep       Date:  2022-01-12       Impact factor: 4.379

8.  The Correlation of Serum Myostatin Levels with Gait Speed in Kidney Transplantation Recipients.

Authors:  Po-Yu Huang; Jen-Pi Tsai; Yen-Cheng Chen; Ming-Che Lee; Bang-Gee Hsu
Journal:  Int J Environ Res Public Health       Date:  2022-01-01       Impact factor: 3.390

9.  Polish Translation and Validation of the Mini Sarcopenia Risk Assessment (MSRA) Questionnaire to Assess Nutritional and Non-Nutritional Risk Factors of Sarcopenia in Older Adults.

Authors:  Roma Krzymińska-Siemaszko; Ewa Deskur-Śmielecka; Arkadiusz Styszyński; Katarzyna Wieczorowska-Tobis
Journal:  Nutrients       Date:  2021-03-24       Impact factor: 5.717

10.  Reference Values for Skeletal Muscle Mass at the Third Lumbar Vertebral Level Measured by Computed Tomography in a Healthy Korean Population.

Authors:  Ja Kyung Yoon; Sunyoung Lee; Kyoung Won Kim; Ji Eun Lee; Jeong Ah Hwang; Taeyong Park; Jeongjin Lee
Journal:  Endocrinol Metab (Seoul)       Date:  2021-06-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.